Pharmaceuticals
Hainan Boao Lecheng International Medical Tourism Pilot Zone holds event to attract Japanese investment
The event is co-organized by Winhealth Pharma BOAO, China, Sept. 23, 2021 /PRNewswire/ -- The Hainan Boao Lecheng International Medical Tourism Pilot Zone ("Lecheng Pilot Zone")'s virtual promotional event to explain the favorable investment policies put in place for Japanese businesses, hosted ...
2021-09-23 16:15
3436
AstraZeneca and Oncoshot establish strategic partnership to better streamline recruitment process for cancer clinical trials
SINGAPORE, Sept. 23, 2021 /PRNewswire/ -- Singapore's cancer population may benefit from improved access to cutting-edge clinical trials through InSite Feasibility - Oncoshot's new digital platform that facilitates the efficient completion of oncology feasibility studies supported by near real-ti...
2021-09-23 16:07
4400
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with Chemotherapy as First-Line Therapy for Esophageal Squamous Cell Carcinoma (ESCC)
SAN FRANCISCO and SUZHOU, China, Sept. 23, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...
2021-09-23 08:00
4583
MedAlliance announces completion of enrollment in Japanese SELUTION SLR™ Study
GENEVA, Sept. 23, 2021 /PRNewswire/ -- MedAlliance, with its Japanese partner MDK Medical, has completed enrollment in the clinical study of its novel Sirolimus Drug Eluting Balloon (DEB), SELUTION SLR™, for the treatment of peripheral arterial disease (PAD). This follows the acceptance of a Clin...
2021-09-23 08:00
3799
Ascentage Pharma's MDM2-p53 Inhibitor Alrizomadlin (APG-115) Granted Fast Track Designation by the US FDA for the Treatment of Relapsed/Refractory Unresectable or Metastatic Melanoma
SUZHOU, China, and ROCKVILLE, MD, Sept 22, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its novel MDM2-p53 inhibitor alrizomadlin (A...
2021-09-23 07:40
2323
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies
VANCOUVER, British Columbia and SHANGHAI, Sept. 23, 2021 /PRNewswire/ --
AbCellera
2021-09-23 06:00
4945
INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico
News follows recent regulatory authorizations to proceed with the trial in Brazil and the Philippines INOVIO and partner Advaccine are collaborating on the global Phase 3 trial in regions underserved by COVID-19 vaccines; to focus onLatin America, Asia, and Africa PLYMOUTH MEETING, Pa., Sept. 2...
2021-09-22 20:00
6463
Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest
* Trial enrolled over 30,000 adult & elderly participants across 4 continents; 100% of SARS-CoV-2 strains observed in efficacy analysis were variants (Delta was predominant strain) * Primary and secondary efficacy endpoints were successfully met * 100% efficacy against severe COVID-19 & hosp...
2021-09-22 18:56
2912
Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Drug
SHELTON, Conn., Sept. 22, 2021 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today on the significant advantages gained by remdesivir encapsulation ...
2021-09-22 18:45
6288
Samsung Biologics showcases its newest CDO process platform, S-Cellerate™, at BPI 2021, offering expedited timeline to IND and BLA
INCHEON, South Korea, Sept. 22, 2021 /PRNewswire/ -- Samsung Biologics, a global contract development and manufacturing organization (CDMO), introduced its proprietary technology platform, S-CellerateTM, at the BioProcess International Conference (BPI 2021) to offer clients an integrated and seam...
2021-09-22 18:00
2304
New Therapy to Treat Advanced Small Cell Lung Cancer ZEPZELCA® (lurbinectedin) Approved in Singapore
Highlights: * ZEPZELCA® (lurbinectedin) is the first new therapy approved in Singapore to treat 2L metastatic small cell lung cancer (SCLC) in 20 years * ZEPZELCA provisional approval represents an important advance for adult patients whose metastatic SCLC has progressed on or after platinum-...
2021-09-22 14:30
2416
Koji Tanabe, CEO of I Peace, Inc. honored by World Biz Magazine with "Top 100 Innovation CEO" Award
PALO ALTO, Calif., Sept. 21, 2021 /PRNewswire/ -- Koji Tanabe, Founder and CEO
of I Peace, Inc. (https://www.ipeace.com
2021-09-22 02:00
2044
FDA Approves LEXETTE (R) for Adolescent Plaque Psoriasis
RALEIGH, N.C., Sept. 21, 2021 /PRNewswire/ -- Mayne Pharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved LEXETTE® (halobetasol propionate) foam, 0.05% for use in adolescents. LEXETTE, a super potent topical corticosteroid, is now approved for the treatment ...
2021-09-21 22:00
5186
Kyowa Hakko Acclaimed by Frost & Sullivan for its Non-GMO, Allergen-free, Immune Support Paraprobiotic Ingredient, IMMUSE™
The solution offers superior ease of formulation, potential application versatility, and more comprehensive immune support compared to probiotics and other immune health ingredients SANTA CLARA, Calif., Sept. 21, 2021 /PRNewswire/ -- Based on its recent analysis of the North American immune hea...
2021-09-21 20:00
1934
Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021
MELBOURNE, Australia and SAN FRANCISCO, Sept. 20, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that data was present...
2021-09-20 22:51
7738
CStone presents clinical data from the China registrational bridging study on ivosidenib in patients with relapsed/refractory acute myeloid leukemia (R/R AML) with a susceptible IDH1 mutation at the 2021 ESMO Congress
* The data showed that ivosidenib demonstrated clinical efficacy in the treatment of Chinese adults with R/R AML with a susceptible IDH1 mutation. And ivosidenib was well tolerated and had a manageable safety profile * In August 2021, the National Medical Products Administration (NMPA) of Chin...
2021-09-20 20:00
5457
Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial
* Rapid oral absorption of BNC210 novel tablet formulation potentially well-suited for acute treatment of anxiety in patients with Social Anxiety Disorder * Phase 2 clinical trial on target to start by end of 2021 and expected to read out topline data by end of 2022 ADELAIDE, Australia, Sept....
2021-09-20 18:00
4590
Appealing Data of CARsgen Therapeutics' CAR-T (CT041) in Advanced Gastric Cancer Presented at ESMO
SHANGHAI, Sept. 19, 2021 /PRNewswire/ -- On September 19, 2021, CARsgen Therapeutics (stock code: 2171.HK) disclosed the latest progress of the investigator-initiated trial (IIT) of Claudin18.2 (CLDN18.2) CAR-T (CT041) for the treatment of digestive system tumors. Results of this trial have been ...
2021-09-20 08:24
10540
CStone presents preliminary results from a phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with the anti-PD-1 mAb CS1003 in patients with advanced solid tumors at ESMO 2021
SUZHOU, China, Sept. 19, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative cancer immunotherapies and precision medicines, today announced the preliminary results from t...
2021-09-19 09:00
4863
2021 CSCO | Henlius will Release Four Oral Presentations of Two Upcoming Commercial Products: Novel anti-PD-1 mAb Serplulimab and Bevacizumab Biosimilar
SHANGHAI, Sept. 18, 2021 /PRNewswire/ -- The 24th Annual Meeting of Chinese Society of Clinical Oncology (CSCO) will be held online and in-person from 25th to 29th September 2021. In this meeting, Henlius will release 4 study results of 2 products to be commercialized, the novel anti-PD-1 mAb ser...
2021-09-18 20:00
12589
Week's Top Stories
Most Reposted
Ascentium Welcomes MGI Dobbyn Carafa, Strengthening Advisory Capability in Australia
[Picked up by 297 media titles]
2026-07-20 15:00
A New Chapter Begins: Peach Blossoms Returns to Level 5 with the Debut of its Black Pearl One Diamond Tasting Journey
[Picked up by 292 media titles]
2026-07-23 16:00
Singapore Tourism Board and Traveloka Renew Partnership to Welcome More Southeast Asian and Australian Travellers to Singapore
[Picked up by 291 media titles]
2026-07-17 18:18
MetaOptics to Deploy its Direct Laser Writer at the University of Arizona's Center of Semiconductor Manufacturing to Advance its U.S. Expansion
[Picked up by 287 media titles]
2026-07-22 07:30Omni HR Launches Native MCP Integration, Connecting AI Assistants to Live HR Data
[Picked up by 286 media titles]
2026-07-20 11:00
Most Read
Singapore Tourism Board and Traveloka Renew Partnership to Welcome More Southeast Asian and Australian Travellers to Singapore
2026-07-17 18:18
14327
Ascentium Welcomes MGI Dobbyn Carafa, Strengthening Advisory Capability in Australia
2026-07-20 15:00
11446